CNTNAP2 and insomnia measurement: The absence of neuromyotonia, neuropathic pain, severe insomnia, or cognitive and psychiatric symptoms argued against Morvan’s syndrome or a primary CASPR2-associated autonomic neuropathy (Masrori et al., 2021).